1.Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment
Hyo Seon RYU ; Hyun Jung KIM ; Woong Bae JI ; Byung Chang KIM ; Ji Hun KIM ; Sung Kyung MOON ; Sung Il KANG ; Han Deok KWAK ; Eun Sun KIM ; Chang Hyun KIM ; Tae Hyung KIM ; Gyoung Tae NOH ; Byung-Soo PARK ; Hyeung-Min PARK ; Jeong Mo BAE ; Jung Hoon BAE ; Ni Eun SEO ; Chang Hoon SONG ; Mi Sun AHN ; Jae Seon EO ; Young Chul YOON ; Joon-Kee YOON ; Kyung Ha LEE ; Kyung Hee LEE ; Kil-Yong LEE ; Myung Su LEE ; Sung Hak LEE ; Jong Min LEE ; Ji Eun LEE ; Han Hee LEE ; Myong Hoon IHN ; Je-Ho JANG ; Sun Kyung JEON ; Kum Ju CHAE ; Jin-Ho CHOI ; Dae Hee PYO ; Gi Won HA ; Kyung Su HAN ; Young Ki HONG ; Chang Won HONG ; Jung-Myun KWAK ;
Annals of Coloproctology 2024;40(2):89-113
		                        		
		                        			
		                        			 Colorectal cancer is the third most common cancer in Korea and the third leading cause of death from cancer. Treatment outcomes for colon cancer are steadily improving due to national health screening programs with advances in diagnostic methods, surgical techniques, and therapeutic agents.. The Korea Colon Cancer Multidisciplinary (KCCM) Committee intends to provide professionals who treat colon cancer with the most up-to-date, evidence-based practice guidelines to improve outcomes and help them make decisions that reflect their patients’ values and preferences. These guidelines have been established by consensus reached by the KCCM Guideline Committee based on a systematic literature review and evidence synthesis and by considering the national health insurance system in real clinical practice settings. Each recommendation is presented with a recommendation strength and level of evidence based on the consensus of the committee. 
		                        		
		                        		
		                        		
		                        	
2.Clinical significance and outcomes of adult living donor liver transplantation for acute liver failure: a retrospective cohort study based on 15-year single-center experience
Geun-hyeok YANG ; Young-In YOON ; Shin HWANG ; Ki-Hun KIM ; Chul-Soo AHN ; Deok-Bog MOON ; Tae-Yong HA ; Gi-Won SONG ; Dong-Hwan JUNG ; Gil-Chun PARK ; Sung-Gyu LEE
Annals of Surgical Treatment and Research 2024;107(3):167-177
		                        		
		                        			 Purpose:
		                        			This study aimed to describe adult living donor liver transplantation (LDLT) for acute liver failure and evaluate its clinical significance by comparing its surgical and survival outcomes with those of deceased donor liver transplantation (DDLT). 
		                        		
		                        			Methods:
		                        			We retrospectively reviewed the medical records of 267 consecutive patients (161 LDLT recipients and 106 DDLT recipients) aged 18 years or older who underwent liver transplantation between January 2006 and December 2020. 
		                        		
		                        			Results:
		                        			The mean periods from hepatic encephalopathy to liver transplantation were 5.85 days and 8.35 days for LDLT and DDLT, respectively (P = 0.091). Among these patients, 121 (45.3%) had grade III or IV hepatic encephalopathy (living, 34.8% vs. deceased, 61.3%; P < 0.001), and 38 (14.2%) had brain edema (living, 16.1% vs. deceased, 11.3%; P = 0.269) before liver transplantation. There were no significant differences in in-hospital mortality (living, 11.8% vs. deceased, 15.1%; P = 0.435), 10-year overall survival (living, 90.8% vs. deceased, 84.0%; P = 0.096), and graft survival (living, 83.5% vs. deceased, 71.3%;P = 0.051). However, postoperatively, the mean intensive care unit stay was shorter in the LDLT group (5.0 days vs. 9.5 days, P < 0.001). In-hospital mortality was associated with vasopressor use (odds ratio [OR], 3.40; 95% confidence interval [CI], 1.45–7.96; P = 0.005) and brain edema (OR, 2.75; 95% CI, 1.16–6.52; P = 0.022) of recipient at the time of transplantation. However, LDLT (OR, 1.26; 95% CI, 0.59–2.66; P = 0.553) was not independently associated with in-hospital mortality. 
		                        		
		                        			Conclusion
		                        			LDLT is feasible for acute liver failure when organs from deceased donors are not available. 
		                        		
		                        		
		                        		
		                        	
3.The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study
Byung-Wook KIM ; Jong Jae PARK ; Hee Seok MOON ; Wan Sik LEE ; Ki-Nam SHIM ; Gwang Ho BAIK ; Yun Jeong LIM ; Hang Lak LEE ; Young Hoon YOUN ; Jun Chul PARK ; In-Kyung SUNG ; Hyunsoo CHUNG ; Jeong Seop MOON ; Gwang Ha KIM ; Su Jin HONG ; Hyuk Soon CHOI
Gut and Liver 2024;18(2):257-264
		                        		
		                        			 Background/Aims:
		                        			Tegoprazan is a novel potassium-competitive acid blocker that has beneficial effects on acid-related disorders such as gastroesophageal reflux and peptic ulcer diseases.This study aimed to validate the effect of tegoprazan on endoscopic submucosal dissection (ESD)-induced artificial ulcers. 
		                        		
		                        			Methods:
		                        			Patients from 16 centers in Korea who underwent ESD for gastric neoplasia were enrolled. After ESD, pantoprazole was administered intravenously for 48 hours. The patients were randomly allocated to either the tegoprazan or esomeprazole group. Tegoprazan 50 mg or esomeprazole 40 mg were administered for 4 weeks, after which gastroscopic evaluation was performed. If the artificial ulcer had not healed, the same dose of tegoprazan or esomeprazole was administered for an additional 4 weeks, and a gastroscopic evaluation was performed. 
		                        		
		                        			Results:
		                        			One hundred sixty patients were enrolled in this study. The healing rates of artificial ulcers at 4 weeks were 30.3% (23/76) and 22.1% (15/68) in the tegoprazan and esomeprazole groups, respectively (p=0.006). At 8 weeks after ESD, the cumulative ulcer healing rates were 73.7% (56/76) and 77.9% (53/68) in the tegoprazan and esomeprazole groups, respectively (p=0.210). Delayed bleeding occurred in two patients in the tegoprazan group (2.6%) and in one patient in the esomeprazole group (1.5%). Other adverse events were negligible in both groups. 
		                        		
		                        			Conclusions
		                        			Tegoprazan showed similar effects on post-ESD artificial ulcer healing in comparison with esomeprazole. 
		                        		
		                        		
		                        		
		                        	
4.Effects of Resilience, Family Support, and Spiritual Well-Being on Posttraumatic Growth in Patients with Lung Cancer Undergoing Chemotherapy
Ha Young MOON ; Ki Sook NAM ; Hye Won OH ; Yeon Soo CHO ; Ju Yeon CHOI
Journal of Korean Clinical Nursing Research 2024;30(2):147-156
		                        		
		                        			 Purpose:
		                        			The purpose of this study is to confirm the effect of resilience, family support, and spiritual well-being on posttraumatic growth(PTG) in lung cancer patients undergoing chemotherapy.  
		                        		
		                        			Methods:
		                        			The study collected data from January 20 to July 6, 2023 on 124 lung cancer patients who were admitted to hospital of C university in Seoul and received chemotherapy treatment. Patients were asked to complete a questionnaire consisting of general characteristics, disease characteristics, resilience, family support, spiritual well-being and PTG. Data were analyzed using t-tests, One-way ANOVA, Pearson's correlation and multiple regression analysis.  
		                        		
		                        			Results:
		                        			The mean score for PTG in lung cancer patients was 55.17, resilience was 72.46, family support was 49.00, and spiritual well-being was 53.50. Significant positive correlations were found for PTG with resilience (r=.62, p<.001), family support (r=.40, p<.001) and spiritual well-being (r=.47, p<.001). Factors contributing to PTG of lung cancer patients were resilience (β=.50, p<.001), spiritual well-being (β=.20, p=.008), and gender (β =.14, p=.043).  
		                        		
		                        			Conclusion
		                        			This study aims to provide basic data for the PTG intervention program by identifying factors affecting the PTG of lung cancer patients. It is necessary to develop new nursing intervention programs to improve PTG for patients with lung cancer based on strategies to enhance resilience and spiritual well-being. 
		                        		
		                        		
		                        		
		                        	
5.High vegetable consumption and regular exercise are associated with better quality of life in patients with gout
Hyunsue DO ; Hyo Jin CHOI ; Byoongyong CHOI ; Chang-Nam SON ; Sang-Hyon KIM ; You-Jung HA ; Ji Hyoun KIM ; Min Jung KIM ; Kichul SHIN ; Hyun-Ok KIM ; Ran SONG ; Sung Won LEE ; Joong Kyong AHN ; Seung-Geun LEE ; Chang Hoon LEE ; Kyeong Min SON ; Ki Won MOON
The Korean Journal of Internal Medicine 2024;39(5):845-854
		                        		
		                        			 Background/Aims:
		                        			The Gout Impact Scale (GIS), a part of the Gout Assessment Questionnaire 2.0, is used to measure gout-specific health-related quality of life (HRQOL). Although several studies have been conducted on the factors affecting the HRQOL of patients with gout, few have focused on lifestyle factors. This study aimed to investigate the correlation between lifestyle habits and HRQOL using the GIS in patients with gout. 
		                        		
		                        			Methods:
		                        			We used data from the Urate-Lowering TheRApy in Gout (ULTRA) registry, a prospective cohort of Korean patients with gout treated at multiple centers nationwide. The patients were aged ≥18 years and met the 2015 American College of Rheumatology/European League Against Rheumatism gout classification criteria. They were asked to complete a GIS and questions regarding their lifestyle habits at enrollment. 
		                        		
		                        			Results:
		                        			The study included 232 patients. ‘Gout concern overall’ scores in the GIS were significantly lower in patients who exercised more frequently and consumed soft drinks and meat less, and ‘well-being during attack’ scores were significantly lower in patients who consumed vegetables and exercised more frequently. The frequency of vegetable consumption had a negative linear relationship with the ‘well-being during attack’ and ‘gout concern during attack’ scores (p = 0.01, p = 0.001, respectively). The frequency of exercise had a negative linear relationship with the ‘gout concern overall’ and ‘gout concern during attack’ scores (p = 0.04 and p = 0.002, respectively). 
		                        		
		                        			Conclusions
		                        			Patients with gout who frequently consumed vegetables and exercised regularly experienced less impact of gout, exhibiting a better GIS that represented HRQOL. 
		                        		
		                        		
		                        		
		                        	
6.Corrigendum to: Cardioprotection via mitochondrial transplantation supports fatty acid metabolism in ischemia-reperfusion injured rat heart
Jehee JANG ; Ki-Woon KANG ; Young-Won KIM ; Seohyun JEONG ; Jaeyoon PARK ; Jihoon PARK ; Jisung MOON ; Junghyun JANG ; Seohyeon KIM ; Sunghun KIM ; Sungjoo CHO ; Yurim LEE ; Hyoung Kyu KIM ; Jin HAN ; Eun-A KO ; Sung-Cherl JUNG ; Jung-Ha KIM ; Jae-Hong KO
The Korean Journal of Physiology and Pharmacology 2024;28(4):391-391
		                        		
		                        		
		                        		
		                        	
7.Cardioprotection via mitochondrial transplantation supports fatty acid metabolism in ischemia-reperfusion injured rat heart
Jehee JANG ; Ki-Woon KANG ; Young-Won KIM ; Seohyun JEONG ; Jaeyoon PARK ; Jihoon PARK ; Jisung MOON ; Junghyun JANG ; Seohyeon KIM ; Sunghun KIM ; Sungjoo CHO ; Yurim LEE ; Hyoung Kyu KIM ; Jin HAN ; Eun-A KO ; Sung-Cherl JUNG ; Jung-Ha KIM ; Jae-Hong KO
The Korean Journal of Physiology and Pharmacology 2024;28(3):209-217
		                        		
		                        			
		                        			 In addition to cellular damage, ischemia-reperfusion (IR) injury induces substantial damage to the mitochondria and endoplasmic reticulum. In this study, we sought to determine whether impaired mitochondrial function owing to IR could be restored by transplanting mitochondria into the heart under ex vivo IR states. Additionally, we aimed to provide preliminary results to inform therapeutic options for ischemic heart disease (IHD). Healthy mitochondria isolated from autologous gluteus maximus muscle were transplanted into the hearts of Sprague–Dawley rats damaged by IR using the Langendorff system, and the heart rate and oxygen consumption capacity of the mitochondria were measured to confirm whether heart function was restored. In addition, relative expression levels were measured to identify the genes related to IR injury. Mitochondrial oxygen consumption capacity was found to be lower in the IR group than in the group that underwent mitochondrial transplantation after IR injury (p < 0.05), and the control group showed a tendency toward increased oxygen consumption capacity compared with the IR group. Among the genes related to fatty acid metabolism, Cpt1b (p < 0.05) and Fads1 (p < 0.01) showed significant expression in the following order: IR group, IR + transplantation group, and control group. These results suggest that mitochondrial transplantation protects the heart from IR damage and may be feasible as a therapeutic option for IHD. 
		                        		
		                        		
		                        		
		                        	
8.Rehabilitation after Repair of Medial Meniscus Posterior Root Tears: A Systematic Review of the Literature
Jin Seong KIM ; Min Ki LEE ; Moon Young CHOI ; Doo Hwan KONG ; Jeong Ku HA ; Jin Goo KIM ; Kyu Sung CHUNG
Clinics in Orthopedic Surgery 2023;15(5):740-751
		                        		
		                        			 Background:
		                        			There is no consensus established on postoperative rehabilitation after medial meniscus posterior root tear (MMPRT) repair, including when and how physicians can apply range of motion (ROM) exercise, weight-bearing (WB), brace use, and return to sports (RTS). The purpose of this study was to systematically review the literature on postoperative rehabilitation characteristics of MMPRT repair regarding ROM, WB, brace use, and RTS. 
		                        		
		                        			Methods:
		                        			A literature search was performed using the Medline/PubMed, Cochrane Central Register of Controlled Trials, and Embase databases. The inclusion criteria were English language, human clinical studies, and studies describing rehabilitation protocols after MMPRT repair such as ROM, WB, brace use, and RTS. Abstracts, case reports, cohort studies, controlled laboratory studies, human cadaveric or animal studies, systematic reviews, and meta-analyses were excluded. 
		                        		
		                        			Results:
		                        			Thirteen studies were included. Of the 12 ROM studies, ROM was started immediately within 1 or 2 days after operation in 6 studies and after 2 to 3 weeks of knee immobilization in the rest. Of the 13 WB studies, partial weight-bearing was initiated 1 to 4 weeks after operation in 8 studies and 6 weeks in the rest. Of the 9 brace studies, patients were immobilized by a splint for 2 weeks in 3 studies, and in the rest, a brace with full extension was applied for 3 to 6 weeks after several days of splint application.Of the 7 RTS studies, RTS was allowed at 6 months in 6 studies and 5 to 7 months in 1 study. 
		                        		
		                        			Conclusions
		                        			This systematic review revealed conservative rehabilitation protocols were more widely adapted as ROM and WB were restricted at certain degrees during postoperative periods in most protocols analyzed. However, it is impossible to identify a consensus on rehabilitation protocols as the protocols analyzed in this review were distinct each other and heterogeneous. In the future, a well-designed comparative study among different rehabilitation protocols is essential to establish a consensus. 
		                        		
		                        		
		                        		
		                        	
9.When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
Hong-Joon SHIN ; Yu-Il KIM ; Youlim KIM ; Chang Youl LEE ; Seung Won RA ; Ji-Yong MOON ; Ki-Suck JUNG ; Kwang Ha YOO ; Kyeong-Cheol SHIN ; Sung-Chul LIM ;
Chonnam Medical Journal 2023;59(3):180-187
		                        		
		                        			
		                        			 Long-acting  2 -agonist (LABA)/long-acting muscarinic-antagonist (LAMA) dual therapy has been found to be more effective than LAMA monotherapy in the treatment of chronic obstructive pulmonary disease (COPD). However, among patients with group B or D COPD, the characteristics of patients for whom LABA/LAMA dual therapy is superior to LAMA monotherapy in minimizing acute exacerbations remain unknown.With data from a prospective COPD cohort, subgroup analyses were conducted to determine whether LABA/LAMA dual therapy was superior to LAMA monotherapy in reducing the rate of acute exacerbations in group B and D COPD patients. Group B and D COPD patients taking LAMA or LABA/LAMA were enrolled according to the 2022 Global initiative for Chronic Obstructive Pulmonary Disease guidelines. A total of 737 patients were included in this study: 600 with group B COPD and 137 with group D COPD. Compared with patients taking LAMA monotherapy, those taking LABA/ LAMA had a significantly lower incidence of acute exacerbations over 1 year. In the subgroup of patients ≥70 years old, there was a significantly lower risk of severe COPD exacerbations among group B patients taking LABA/LAMA than among those taking LAMA monotherapy (odds ratio [OR], 0.258; 95% confidence interval [CI], 0.095– 0.703). In contrast, in the subgroup of group D patients with COPD Assessment Test scores ≥25, compared with LAMA monotherapy, LABA/LAMA treatment was associated with lower risk of severe COPD exacerbations (OR, 0.115; 95% CI, 0.018-0.749).The combination of LABA and LAMA was found to be superior to LAMA monotherapy, especially for treating older adults with group B COPD, as well as for group D patients with severe symptoms. 
		                        		
		                        		
		                        		
		                        	
10.Use of Antibiotics Within the Last 14 Days of Life in Korean Patients:A Nationwide Study
Yu Mi WI ; Ki Tae KWON ; Soyoon HWANG ; Sohyun BAE ; Yoonjung KIM ; Hyun-Ha CHANG ; Shin-Woo KIM ; Hae Suk CHEONG ; Shinwon LEE ; Dong Sik JUNG ; Kyung Mok SOHN ; Chisook MOON ; Sang Taek HEO ; Bongyoung KIM ; Mi Suk LEE ; Jian HUR ; Jieun KIM ; Young Kyung YOON ; And Antimicrobial Stewardship Research Committee of Korean Society for Antimicrobial Therapy
Journal of Korean Medical Science 2023;38(9):e66-
		                        		
		                        			 Background:
		                        			Antimicrobial prescriptions for serious chronic or acute illness nearing its end stages raise concerns about the potential for futile use, adverse events, increased multidrugresistant organisms, and significant patient and social cost burdens. This study investigated the nationwide situation of how antibiotics are prescribed to patients during the last 14 days of life to guide future actions. 
		                        		
		                        			Methods:
		                        			This nationwide multicenter retrospective cohort study was conducted at 13 hospitals in South Korea from November 1 to December 31, 2018. All decedents were included in the study. Antibiotic use during the last two weeks of their lives was investigated. 
		                        		
		                        			Results:
		                        			A total of 1,201 (88.9%) patients received a median of two antimicrobial agents during the last two weeks of their lives. Carbapenems were prescribed to approximately half of the patients (44.4%) in the highest amount (301.2 days of therapy per 1,000 patient-days).Among the patients receiving antimicrobial agents, 63.6% were inappropriate and only 327 patients (27.2%) were referred by infectious disease specialists. The use of carbapenem (odds ratio [OR], 1.51; 95% confidence interval [CI], 1.13–2.03; P = 0.006), underlying cancer (OR, 1.56; 95% CI, 1.20–2.01, P = 0.047), underlying cerebrovascular disease (OR, 1.88; 95% CI, 1.23–2.89, P = 0.004), and no microbiological testing (OR, 1.79; 95% CI, 1.15–2.73; P = 0.010) were independent predictors for inappropriate antibiotic prescribing. 
		                        		
		                        			Conclusion
		                        			A considerable number of antimicrobial agents are administered to patients with chronic or acute illnesses nearing their end-of-life, a high proportion of which are prescribed inappropriately. Consultation with an infectious disease specialist, in addition to an antimicrobial stewardship program, may be necessary to induce the optimal use of antibiotics. 
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail